Browsing by Author "Herzog, T."

Now showing 1 - 4 of 4

Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy
(Impact Journals, 2017) Carter, P.; Alifrangis, C.; Cereser, B.; Chandrasinghe, P.; Del Bel Belluz, L.; Fotopoulou, C.; Frilling, A.; Herzog, T.; Moderau, N.; Tabassum, N.; Krell, J.; Stebbing, J.
Tumor molecular profiling has enabled selection of targeted therapies in a host of solid tumors. Here we used a retrospective clinical cohort, to evaluate the benefit of tailoring treatments for female genital tract malignancy, using tumor molecular profiles. Clinical outcome data for 112 patients was retrospectively separated into two groups. These either followed a matched treatment plan that incorporated at least one drug recommended according to their tumor profile and none that were expected to have no benefit (64 patients), or was unmatched with suggested treatments and received at least one drug that was anticipated to lack benefit for that tumor (48 patients). In the group of patients whose drugs matched those recommended by molecular profiling of their tumor, their overall survival was 593 days on average, compared to 449 days for patients that did not; removing drugs predicted to have no benefit from treatment regimens received after profiling increased survival by 144 days on average (P = 0.0265). In the matched treatment group, 30% of patients had died by the last time of monitoring, whereas this was 40% in the unmatched group (P = 0.2778). The IHC biomarker for the progesterone receptor was demonstrated to be prognostic for survival.
Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy
(Impact Journals, 2018) Carter, P.; Alifrangis, C.; Cereser, B.; Chandrasinghe, P.; Del Bell Belliz, Z.; Fotopoulou, C.; Frilling, A.; Herzog, T.; Moderau, N.; Tabassum, N.; Krell, J.; Stebbing, J.
[This corrects the article DOI: 10.18632/oncotarget.23675.]. Erratum for : Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy. [Oncotarget. 2017; 9(5):6007-6014]
Correction: Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?
(Impact Journals LLC, 2018) Carter, P.; Alifrangis, C.; Cereser, B.; Chandrasinghe, P.; Del Bel Belluz, L.; Herzog, T.; Levitan, J.; Moderau, N.; Schwartzberg, L.; Tabassum, N.; Wen, J.; Krell, J.; Stebbing, J.
This corrects the article DOI: 10.18632/oncotarget.24258.]. Erratum for Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? [Oncotarget. 2018 ;9(10):9456-9467]
Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?
(Impact Journals, 2018) Carter, P.; Alifrangis, C.; Cereser, B.; Chandrasinghe, P.; Del Bel Belluz, L.; Herzog, T.; Levitan, J.; Moderau, N.; Schwartzberg, L.; Tabassum, N.; Wen, J.; Krell, J.; Stebbing, J.
We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers.Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations.The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34% of patients were deceased at the completion of monitoring, whereas this was 47% in the unmatched group (P = 0.0001).